Chimeric antigen receptor (CAR) T-cell therapies hold great promise for the treatment of both hematologic cancers and solid cancers. However, they also pose unique challenges for bioanalysis. For example, different CAR T-cell therapies designed to treat different cancers typically require different testing regimes. Another challenge is that regulatory expectations for CAR T-cell therapies are in flux.
When faced with daunting bioanalysis challenges, developers and sponsors of CAR T-cell therapies needn’t “go it alone.” They can keep their programs on track by partnering with companies that offer specialized laboratory services. Partner candidates should be able to help clients navigate the issues summarized in this article.
